Finance ❯ Stock Market

Pharmaceutical Stocks

Market Reactions Novo Nordisk Eli Lilly Eli Lilly Stock Market Performance Investor Sentiment Novo Nordisk Shares Company Performance Novo Nordisk Stock Moderna

FDA Approves Eli Lilly’s Once‑Weekly Basal Insulin Onswik

It widens options for adults with type 2 diabetes by cutting injection burden after phase 3 data showed similar A1C control to daily insulins.

Novartis' Pelacarsen Fails Phase 3 After Lowering Lp(a)

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

Capricor Seeks New FDA Path for Duchenne Drug After 9–3 Advisory Vote

Viking Therapeutics Rallies as Weight‑Loss Program Moves Toward Late‑Stage Testing

CVS Caremark Reverses Exclusion and Adds Lilly’s Foundayo and Zepbound to Its Formulary

FDA Grants Accelerated Approval to Kresladi, First Gene Therapy for Severe Pediatric LAD-1

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

FDA Warns 30 Telehealth Firms Over Misleading Ads for Compounded GLP-1 Drugs

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

Lupin Strikes Semaglutide Licensing Deal With Galenicum Covering 23 Countries

FDA Approves First Wegovy Pill for Chronic Weight Management

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

FDA Clears Arrowhead’s Redemplo for FCS, Marking the Biotech’s First Approval

EU Searches Sanofi Sites in Flu Vaccine Antitrust Probe

Alembic Pharma Secures USFDA Approval for Liposomal Doxorubicin ANDA

Trump Signs Executive Order to Slash U.S. Drug Prices by Up to 80%